Close

Auxilium's (AUXL) Testosterone Gel Growth Encouraging, Say Analysts

Go back to Auxilium's (AUXL) Testosterone Gel Growth Encouraging, Say Analysts

Auxilium Pharmaceuticals (AUXL) Posts Q3 Loss of 21c/Share; Boosts FY12 Outlook

November 7, 2012 7:30 AM EST

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) reported Q3 EPS of ($0.21), $0.17 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $71 million versus the consensus estimate of $79.35 million.

Sees FY2012 revenue of $388-408 million, versus prior guidance of $310-331 million and the... More